 Fennec Pharmaceuticals Inc. FENC FRX.TO, a specialty pharmaceutical company focused on the development of PEDMARKTM a unique formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the closing of its previously announced underwritten public offering of 4,800,000 common shares at a public offering price of 6.25 per share. In addition, Fennec has granted the underwriters a 30-day option to purchase up to an additional 720,000 common shares. A final prospectus supplement and the accompanying prospectus relating to and describing the offering was filed with the SEC. 